{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:43Z","timestamp":1787844223345,"version":"build-2784847793"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Migraine is the most prevalent neurological disorder and the leading cause of disability in individuals under 50 years of age. Two types of migraine therapies have been defined: acute therapy (abortive or symptomatic treatment), the purpose of which is to interrupt migraine attacks, and preventive treatment (prophylactic treatment), the purpose of which is to reduce the frequency and severity of migraine attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This paper reviews research advances in new agents for acute therapy of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>This review provides an overview of emerging new drugs for acute treatment of migraine based on clinical evidence and summarizes the milestones of different stages of clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two new formulations of sumatriptan, DFN-11 (3 mg doses of subcutaneous sumatriptan) and DFN-02 (a nasal spray of sumatriptan 10 mg and a permeation-enhancing excipient), have been developed, and both of them showed a fast-onset action with efficacy for acute treatment of migraine with fewer adverse events. New drug discovery programs shifted the focus to the development of ditans, a group of antimigraine drugs targeting 5-HT\n                      <jats:sub>1F<\/jats:sub>\n                      receptors. Only lasmiditan has progressed to phase III clinical trials and was finally approved by the Food and Drug Administration (FDA) for acute migraine treatment. The other target for acute therapy is CGRP receptor antagonists, namely, gepants. Ubrogepant and rimegepant demonstrated statistically significant efficacy, and both were recently approved by the FDA. These 5-HT\n                      <jats:sub>1F<\/jats:sub>\n                      receptor agonists and CGRP receptor antagonists did not cause vasoconstriction, offering advantages over the current mainstay of specific acute migraine treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Overall, these new agents have expanded the available acute therapies for migraine treatment and will likely change the strategy with which we treat patients with migraine in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.315995","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T04:19:32Z","timestamp":1621138772000},"page":"S25-S42","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Acute Treatment of Migraine"],"prefix":"10.4103","volume":"69","author":[{"given":"Chun-Pai","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Mao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240907","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Disease","year":"2017","journal-title":"Lancet"},{"key":"R3-5-20240907","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia"},{"key":"R4-5-20240907","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.bjp.0703587","article-title":"Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: Effect of selective 5-HT (1F) receptor agonists and PGF (2alpha)","volume":"131","author":"Cohen","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R5-5-20240907","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","article-title":"5-HT1F receptor agonists in acute migraine treatment: A hypothesis","volume":"23","author":"Ramadan","year":"2003","journal-title":"Cephalalgia"},{"key":"R6-5-20240907","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"R7-5-20240907","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"R8-5-20240907","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"R9-5-20240907","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"R10-5-20240907","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"R11-5-20240907","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s10194-017-0740-3","article-title":"A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine","volume":"18","author":"Munjal","year":"2017","journal-title":"J Headache Pain"},{"key":"R13-5-20240907","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1021\/acs.molpharmaceut.7b00297","article-title":"Dodecylmaltoside modulates bicellular tight junction contacts to promote enhanced permeability","volume":"14","author":"Gradauer","year":"2017","journal-title":"Mol Pharm"},{"key":"R14-5-20240907","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/head.12905","article-title":"A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults","volume":"56","author":"Munjal","year":"2016","journal-title":"Headache"},{"key":"R15-5-20240907","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/head.13309","article-title":"DFN-02 (Sumatriptan 10 mg with a permeation enhancer) nasal spray vs. placebo in the acute treatment of migraine: A double-blind, placebo-controlled study","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"R16-5-20240907","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40263-019-00614-6","article-title":"DFN-02, Sumatriptan 10 mg nasal spray with permeation enhancer, for the acute treatment of migraine: A randomized, double-blind, placebo-controlled study assessing functional disability and subject satisfaction with treatment","volume":"33","author":"Lipton","year":"2019","journal-title":"CNS Drugs"},{"key":"R18-5-20240907","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.CIR.98.1.25","article-title":"Coronary side-effect potential of current and prospective antimigraine drugs","volume":"98","author":"MaassenVanDenBrink","year":"1998","journal-title":"Circulation"},{"key":"R19-5-20240907","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2.2.123","article-title":"Safety profile of the triptans","volume":"2","author":"Tepper","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"R20-5-20240907","first-page":"27","article-title":"Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache","volume":"6","author":"Moore","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"R21-5-20240907","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10194-016-0717-7","article-title":"Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine","volume":"18","author":"Cady","year":"2017","journal-title":"J Headache Pain"},{"key":"R22-5-20240907","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1526-4610.2003.03006.x","article-title":"Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment","volume":"43","author":"Gallagher","year":"2003","journal-title":"Headache"},{"key":"R23-5-20240907","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-018-0881-z","article-title":"Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: A multicenter, randomized, double-blind, placebo-controlled study","volume":"19","author":"Landy","year":"2018","journal-title":"J Headache Pain"},{"key":"R24-5-20240907","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0028-3908(99)00032-5","article-title":"Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis","volume":"38","author":"Cutrer","year":"1999","journal-title":"Neuropharmacology"},{"key":"R25-5-20240907","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1468-2982.2001.00208.x","article-title":"Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine","volume":"21","author":"Gomez-Mancilla","year":"2001","journal-title":"Cephalalgia"},{"key":"R26-5-20240907","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(99)00067-9","article-title":"Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis","volume":"369","author":"Mitsikostas","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R27-5-20240907","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"R28-5-20240907","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ramirez","year":"2020","journal-title":"Pain"},{"key":"R29-5-20240907","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","article-title":"Selective seratonin 1F (5-HT (1F)) receptor agonist LY334370 for acute migraine: A randomised controlled trial","volume":"358","author":"Goldstein","year":"2001","journal-title":"Lancet"},{"key":"R30-5-20240907","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2018.1552939","article-title":"Emerging drugs for migraine treatment: An update","volume":"23","author":"Lambru","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"R31-5-20240907","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/0333102419859313","article-title":"Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine","volume":"39","author":"Doty","year":"2019","journal-title":"Cephalalgia"},{"key":"R32-5-20240907","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","article-title":"Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN","volume":"39","author":"Krege","year":"2019","journal-title":"Cephalalgia"},{"key":"R33-5-20240907","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"Shapiro","year":"2019","journal-title":"J Headache Pain"},{"key":"R36-5-20240907","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: New drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J Headache Pain"},{"key":"R37-5-20240907","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s11739-016-1489-4","article-title":"Anti-CGRP monoclonal antibodies in migraine: Current perspectives","volume":"11","author":"Giamberardino","year":"2016","journal-title":"Intern Emerg Med"},{"key":"R38-5-20240907","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1474-4422(17)30126-6","article-title":"Challenging chronic migraine: Targeting the CGRP receptor","volume":"16","author":"Giamberardino","year":"2017","journal-title":"Lancet Neurol"},{"key":"R41-5-20240907","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/0333102418768095","article-title":"CGRP-A target for acute therapy in migraine: Clinical data","volume":"39","author":"Messina","year":"2019","journal-title":"Cephalalgia"},{"key":"R42-5-20240907","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s13311-018-0617-4","article-title":"Targeted CGRP small molecule antagonists for acute migraine therapy","volume":"15","author":"Holland","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R43-5-20240907","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/0333102415584308","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine","volume":"36","author":"Ho","year":"2016","journal-title":"Cephalalgia"},{"key":"R44-5-20240907","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"R45-5-20240907","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: A double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol"},{"key":"R46-5-20240907","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/head.13682","article-title":"Long-term safety evaluation of ubrogepant for the acute treatment of migraine: Phase 3, randomized, 52-week extension trial","volume":"60","author":"Ailani","year":"2020","journal-title":"Headache"},{"key":"R47-5-20240907","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs. placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"R48-5-20240907","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/0333102419869918","article-title":"Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"R49-5-20240907","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"key":"R50-5-20240907","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia"},{"key":"R51-5-20240907","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/cts.12728","article-title":"Ubrogepant is not associated with clinically meaningful elevations of alanine aminotransferase in healthy adult males","volume":"13","author":"Ankrom","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R52-5-20240907","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial","volume":"34","author":"Marcus","year":"2014","journal-title":"Cephalalgia"},{"key":"R53-5-20240907","first-page":"1336","article-title":"Efficacy, safety, and tolerability of rimegepant 75 Mg, an oral CGRP receptor antago- nist, for the acute treatment of migraine: Results from a double- blind, randomized, placebo-controlled trial, study 301","volume":"58","author":"RB","year":"2018","journal-title":"Headache"},{"key":"R54-5-20240907","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"key":"R55-5-20240907","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"key":"R57-5-20240907","first-page":"180","article-title":"A single dose of Rimegepant 75 mg provides pain relief and return to normal function: Results from 3 phase 3 trials in adults with migraine","volume":"59","author":"Lipton","year":"2019","journal-title":"Headache"},{"key":"R58-5-20240907","first-page":"195","article-title":"A single dose of rimegepant 75 mg provides pain relief and return to normal function: Results from 3 phase 3 trials in adults with migraine","volume":"39","author":"Friedman","year":"2019","journal-title":"Cephalalgia"},{"key":"R60-5-20240907","first-page":"177","article-title":"Rimegepant is e ective for the acute treatment of migraine in subjects taking concurrent preventive medication: Results from 3 phase 3 trials","volume":"59","author":"Dodick","year":"2019","journal-title":"Headache"},{"key":"R61-5-20240907","first-page":"175","article-title":"Rimegepant 75 mg is effective for the acute treatment of migraine regardless of attack frequency: Results from 3 phase 3 trials","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:13:55Z","timestamp":1787843635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315995"}},"subtitle":["What has Changed in Pharmacotherapies?"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":52,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.315995","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}